After months of anticipation, Supreme Court justices heard arguments on Wednesday about a long-standing tactic used by generic drug companies to carve out a distinct market for a medicine—and did not appear inclined to alter legal standards for the maneuver.
At issue is skinny labeling, a strategy employed by generic manufacturers to seek regulatory approval for marketing a drug for a specific use, while excluding other patented uses prescribed by brand-name medicines. For example, a generic drug could be approved to treat one type of heart condition but not another, thereby reducing the risk of patent infringement lawsuits.
This tactic has been a key tool for generic companies since the Hatch-Waxman Act was signed into law more than four decades ago. The legislation established the framework for generic drugs to enter the market more easily, with skinny labeling serving as one method Congress used to foster competition and benefit consumers.
Related articles
FDA Drug Center Acting Director Tracy Beth Høeg Departs Amid Leadership Changes
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
UK Political Shake-Up Could Reshape Global Drug Pricing Policies
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congrats on...
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
Supreme Court Allows Telehealth Abortion Access for Mifepristone Pending Legal Battle
On Thursday, the Supreme Court ruled that one of the drugs in a highly effective two-drug regime for medication abortion can remain accessible via tel...
Mail-Order Abortion Pills Remain Legal Amid Legal Uncertainty
In a discussion about the best fruits, my STAT colleague Alexa Lee and I agreed that peaches have been mid in recent years. Is this just a New York Ci...
FDA Rejects Melanoma Drug RP1 Amid Leadership Controversy Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw th...
Why Changing Pill Colors and Shapes at 73 Are More Than Just an Annoyance
At the ripe old age of 73, I take six drugs — four prescription and two over-the-counter pills — every day. I keep careful track of them. But recently...
U.S. Pressures Germany to Increase Payments for Prescription Drugs Amid Trade Tensions
WASHINGTON — Over a recent breakfast, U.S. officials had a message for the German ambassador: pay more for pharmaceuticals. The meeting, between U.S....